Emcure Pharmaceuticals (EMCURE) Q3 25/26 earnings summary

Executive summary

• FY26 Q3 delivered consolidated revenue of INR 2,363 crore, up 20.4% year-over-year, with strong execution of a five-year strategic roadmap focused on growth and innovation despite a challenging macro environment.

• Profit after tax for the quarter was INR 231 crore, a 48% increase year-over-year, and EBITDA reached INR 460 crore, up 27.2% YoY.

• Exclusive partnership with Novo Nordisk enabled the first-mover launch of semaglutide (Poviztra) in India, strengthening the innovation pipeline and presence in the weight management segment.

• Domestic business sales reached INR 1,025 crore (up 15.4% YoY), while international business sales were INR 1,338 crore (up 24.5% YoY).

• Government support for biologics and biosimilars aligns with the company’s robust biotherapeutics portfolio and future growth plans.

Financial highlights

• Revenue from operations grew 20.4% year-over-year to INR 2,363 crore in Q3 FY26.

• Gross margin was 59.3% (down from 60.1% YoY), mainly due to business mix and in-licensing impact.

• EBITDA margin improved to 19.5% from 18.4% YoY.

• PAT margin for the quarter was 9.8%, up from 7.9% YoY.

• Earnings per share (EPS) for the quarter stood at INR 12.16.

Outlook and guidance

• Expectation to continue outpacing industry growth in both domestic and international markets over the next 3-5 years, targeting low- to mid-teens CAGR.

• EBITDA margin expected to improve by 300-400 bps over 3-5 years, aiming for 23-24% by FY29.

• Gross margins anticipated to remain around 60%, with international business growth potentially causing slight downward movement.

• Management remains focused on margin improvement and strong growth through investments in R&D, people, and differentiated product launches.

• Net debt (INR 1,203 crore) expected to be eliminated by FY28, barring major acquisitions.